pubmed.ncbi.nlm.nih.gov

Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma - PubMed

  • ️Fri Jan 01 2010

Review

Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma

Francine M Ducharme et al. Cochrane Database Syst Rev. 2010.

Abstract

Background: In asthmatic patients inadequately controlled on inhaled corticosteroids and/or those with moderate persistent asthma, two main options are recommended: the combination of a long-acting inhaled ss2 agonist (LABA) with inhaled corticosteroids (ICS) or use of a higher dose of inhaled corticosteroids.

Objectives: To determine the effect of the combination of long-acting ss(2) agonists and inhaled corticosteroids compared to a higher dose of inhaled corticosteroids on the risk of asthma exacerbations, pulmonary function and on other measures of asthma control, and to look for characteristics associated with greater benefit for either treatment option.

Search strategy: We identified randomised controlled trials (RCTs) through electronic database searches (MEDLINE, EMBASE and CINAHL), bibliographies of RCTs, clinical trial registries and correspondence with manufacturers until May 2008.

Selection criteria: RCTs that compared the combination of inhaled LABA and ICS to a higher dose of inhaled corticosteroids, in children and adults with asthma.

Data collection and analysis: Two authors independently assessed methodological quality and extracted data. We obtained confirmation from the trialists when possible. The primary endpoint was the number of patients experiencing one or more asthma exacerbations requiring oral corticosteroids.

Main results: This review included 48 studies (15,155 participants including 1155 children and 14,000 adults). Participants were inadequately controlled on their current ICS regimen, experiencing ongoing symptoms and with generally moderate (FEV1 60% to 79% of predicted) airway obstruction. The studies tested the combination of salmeterol or formoterol with a median dose of 400 mcg/day of beclomethasone or equivalent (BDP-eq) compared to a median of 1000 mcg/day of BDP-eq, usually for 24 weeks or less. There was a statistically significantly lower risk of exacerbations requiring systemic corticosteroids in patients treated with LABA and ICS (RR 0.88, 95% CI 0.78 to 0.98, 27 studies, N = 10,578) from 11.45% to 10%, with a number needed to treat of 73 (median study duration: 12 weeks). The study results were dominated by adult studies; trial data from three paediatric studies showed a trend towards increased risk of rescue oral steroids (RR 1.24, 95% CI 0.58 to 2.66) and hospital admission (RR 2.21, 95% CI 0.74 to 6.64) associated with combination therapy. Overall, there was no statistically significant difference in the risk ratios for either hospital admission (RR 1.02, 95% CI 0.67 to 1.56) or serious adverse events (RR 1.12, 95% CI 0.91 to 1.37). The combination of LABA and ICS resulted in significantly greater but modest improvement from baseline in lung function, symptoms and rescue medication use than with higher ICS dose. Despite no significant group difference in the risk of overall adverse events (RR 0.99, 95% CI 0.95 to 1.03), there was an increase in the risk of tremor (RR 1.84, 95% CI 1.20 to 2.82) and a lower risk of oral thrush (RR 0.58, 95% CI 0.40 to 0.86)) in the LABA and ICS compared to the higher ICS group. There was no significant difference in hoarseness or headache between the treatment groups. The rate of withdrawals due to poor asthma control favoured the combination of LABA and ICS (RR 0.65, 95% CI 0.51 to 0.83).

Authors' conclusions: In adolescents and adults with sub-optimal control on low dose ICS monotherapy, the combination of LABA and ICS is modestly more effective in reducing the risk of exacerbations requiring oral corticosteroids than a higher dose of ICS. Combination therapy also led to modestly greater improvement in lung function, symptoms and use of rescue ss(2) agonists and to fewer withdrawals due to poor asthma control than with a higher dose of inhaled corticosteroids. Apart from an increased rate of tremor and less oral candidiasis with combination therapy, the two options appear relatively safe in adults although adverse effects associated with long-term ICS treatment were seldom monitored. In children, combination therapy did not lead to a significant reduction, but rather a trend towards an increased risk, of oral steroid-treated exacerbations and hospital admissions. These trends raised concern about the safety of combination therapy in view of modest improvement in children under the age of 12 years.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Literature flow diagram for June 2008 update of the review.

Figure 2
Figure 2

Methodological quality summary: review authors’ judgements about each methodological quality item for each included study.

Figure 3
Figure 3

Forest plot of comparison: 1 LABA + ICS versus higher dose ICS, outcome: 1.1 # patients with exacerbations requiring oral steroids.

Figure 4
Figure 4

Funnel plot of comparison: 1 LABA + ICS versus higher dose ICS, outcome: 1.1 # patients with exacerbations requiring oral steroids.

Figure 5
Figure 5

Forest plot of comparison: 2 LABA + ICS versus higher dose ICS (subgroup and sensitivity analyses), outcome: 2.4 # patients requiring oral steroids: children versus adults.

Update of

Similar articles

Cited by

References

References to studies included in this review

    1. Baraniuk J, Murray JJ, Nathan RA, Berger WE, Johnson M, Edwards LD, et al. Fluticasone alone or in combination with salmeterol versus triamcinolone in asthma. Chest. 1999;116(3):625–32. - PubMed
    2. Cook D, Srebro SH, Rogenes PR, Rickard K, Edwards L, Johnson MC. A comparison of the safety and efficacy of fluticasone, triamcinolone, and fluticasone plus salmeterol in patients with mild to moderate asthma. American Journal of Respiratory and Critical Care Medicine. 1998;Vol. 157(issue Suppl 3):A416.

    3. *

    4. Johnson MC, Srebro SH, Rogenes PR, Rickard K, Edwards L. A comparison of physician-rated and patient-rated outcomes in a study with fluticasone, triamcinolone, and fluticasone plus salmeterol. American Journal of Respiratory and Critical Care Medicine. 1998;Vol. 157(issue Suppl 3):A414.
    1. Bateman ED, Bantje TA, Gomes MJ, Toumbis MG, Huber RM, Naya I, et al. Combination therapy with a single inhaler budesonide/formoterol compared with high dose fluticasone propionate alone in patients with moderate persistent asthma. American Journal of Respiratory Medicine. 2003;2(3):275–81. - PubMed
    2. Bateman ED, Bantje TA, Joao Gomes M, Toumbis M, Huber R, Eliraz A. Early and sustained benefits of budesonide and formoterol in a single inhaler versus fluticasone in moderate asthma. European Respiratory Journal. 2001;Vol. 18(issue Suppl 33):157s.
    3. Bateman ED, Bantje TA, Joao Gomes M, Toumbis M, Huber R, Eliraz A, et al. Symbicort (budesonide/ eformoterol) turbohaler controls asthma more effectively than fluticasone diskus. Thorax. 2001;Vol. 56(issue Suppl 3):iii 63.
    4. Ericsson K, Bantje TA, Huber H, Borg S. Symbicort® turbuhaler® is more cost effective than fluticasone diskus™ in the treatment of asthma. Annual Thoracic Society 97th International Conference; San Francisco CA. May 18-23.2001.
    5. Ericsson K, Bantje TA, Huber R, Borg S, Anderson F. Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma. European Respiratory Journal. 2001;Vol. 18(issue Suppl 33):157s.
    6. Ericsson K, Bantje TA, Huber RM, Borg S, Bateman ED. Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma. Respiratory Medicine. 2006;100(4):586–94. - PubMed

    7. *

    8. SD-039-0618 Efficacy of Symbicort Turbuhaler® compared with fluticasone Diskus in asthmatic patients. 2005 http://www.astrazeneca.com.
    1. Bateman E, Atienza T, Mihaescu T, Duggan M, Jacques L, Goldfrad C. Asthma control is maintained if treatment with fluticasone propionate/salmeterol (FSC; Advair®/ Seretide®) is stepped down. Annual American Thoracic Society 101st International Conference.2005. p. C12.
    2. Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. Journal of Allergy and Clinical Immunology. 2006;117(3):563–70. - PubMed

    3. *

    4. Glaxo Smith Kline (SAS30040) A 12-week, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination 50/100mcg bd with fluticasone propionate 250mcg bd, all via the DISKUS™/ACCUHALER™ on maintaining asthma control in moderate persistent asthmatic subjects whose symptoms have been well-controlled following an initial maintenance therapy with salmeterol/fluticasone propionate 50/250mcg combination twice-daily for 12 weeks. 2005 http://www.ctr.gsk.co.uk.
    1. Bergmann KC, Lindemann L, Braun R, Steinkamp G. Salmeterol/fluticasone propionate (50/250 mug) combination is superior to double dose fluticasone (500 mug) for the treatment of symptomatic moderate asthma: a prospective, double-blind trial. Swiss Medical Weekly. 2004;134(3-4):50–8. - PubMed

    2. *

    3. Glaxo Smith Kline (SAS40009) A multi-centre, randomised, double-blind, parallel group comparison of the salmeterol/ fluticasone propionate combination product (50/250μg) via Diskus twice daily versus fluticasone propionate (500μg) via Diskus twice daily in patients with moderate asthma (SAS 40009 local German study) 2005 http://www.ctr.gsk.co.uk.
    1. Bouros D, Bachlitzanakis N, Kottakis J, Pfister P, Polychronopoulos V, Papadakis E, et al. Foromoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. European Respiratory Journal. 1999;14(3):627–32. - PubMed

References to studies excluded from this review

    1. Aalbers R, Backer V, Kava TTK, Omenaas ER, Sandstrom T, Jorup C, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Current Medical Research & Opinion. 2004;20(2):225–40. - PubMed
    2. Aalbers R, Backer V, Kava TTK, Welte T, Omenaas ER, Bergqvist PBF, et al. Adjustable dosing with budesonide/ formoterol reduces the rate of asthma exacerbations compared with fixed dosing salmeterol/fluticasone. European Respiratory Society. 2003:2–20.
    3. Aalbers R, Backer V, Kava TTK, Welte T, Omenaas ER, Bergqvist PBF, et al. Improvements in FEV1 are greater with budesonide/formoterol than with salmeterol/fluticasone. European Respiratory Society. 2003:P2–19.
    4. Aalbers R, Backer V, Kava TTK, Welte T, Omenaas ER, Bergqvist PBF, et al. Is well-controlled asthma weeks a useful measure? Fewer exacerbations in patients treated with budesonide/formoterol than salmeterol/fluticasone. European Respiratory Society. 2003:P2–18.
    5. Welte T, Aalbers R, Naya I. Budesonide/formoterol adjustable maintenance dosing (B/F AMD) reduces the burden of asthma more effectively than fixed-dosing (FD) with B/F or salmeterol/fluticasone (S/FL) European Respiratory Journal. 2004;24(Suppl 48):508s.
    1. Adinoff AD, Schwartz HJ, Rickard KA, Yancey SW, Swearingen BE. Salmeterol compared with current therapies in chronic asthma. Journal of Family Practice. 1998;47(4):278–84. - PubMed
    1. Akpinarli A, Tuncer A, Saraclar Y, Sekerel BE, Kalayci O. Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial. Archives of Disease in Childhood. 1999;81:45–8. - PMC - PubMed
    1. Ankerst J, Persson G, Weibull E. Cardiovascular effects of a high dose of the budesonide/formoterol single inhaler in asthmatic patients. European Respiratory Journal. 2001;18(Suppl 33):53s.
    2. Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulmonary Pharmacology & Therapeutics. 2003;16:147–51. - PubMed
    1. Anonymous Levalbuterol for asthma. Drugs & Therapeutics. 1999;Vol. 41(issue 1054):51–3. - PubMed

References to studies awaiting assessment

    1. Boskovska MI, Dokic D, Busletic-Bozinovska K, Arbutina S, Goseva Z. Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilator vis a vis doubling the dose of inhaled corticosteroid in asthma patients. European Respiratory Journal. 2001;(issue Suppl 33):98s.
    1. Currie GP, Stenback S, Lipworth BJ. Dissociation in effects of fluticasone but not fluticasone/salmeterol on lung function and airway hyperresponsiveness in mild persistent asthma. European Respiratory Society Annual Congress. 2002:385s.
    1. Djordjevic D, Zickovic D, Stankovic I, Pejcic T, Ducic J, Rancic M, et al. European Respiratory Society. Madrid, Spain: Oct 9-13, 1999. Comparative study of three months treatment in combination of salmeterol and beclomethasone dipropionate (bdp) with doubling the dose of bdp in mild asthma; p. 849. 1999.
    1. Ozkaya O, Turktas I, Cengizlier R. European Respiratory Society. Madrid, Spain: Oct 9-13, 1999. Low dose budesonide plus formoterol versus high dose budesonide in children with bronchial asthma; p. P365. 1999.
    1. Stankovic IJ, Djordjevic DV, Pejcic TA, Zivkovic DS, Rancic MR, Ristic LM, et al. Formoterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in asthma patients. European Respiratory Journal. 2000;16(Suppl 31):455s.

References to ongoing studies

    1. Aziz I. Comparison of anti inflammatory effect of once daily inhaled formoterol and once daily inhaled budesonide on inflammatory markers in asthmatic patients. Clinical Pharmacology, Ninewells Hospital and Medical School, University of Dundee, DUNDEE, DD1 9SY; Scotland UK:
    1. Barnes NC. Respiratory Medicine, London Chest Hospital. Bonner Road, London, E2 9JX, United Kingdom: A randomized parallel 3 arm study to assess asthma control, lung function, costs and quality of life in patients with asthma treated with formoterol twice daily and either budesonide once or twice daily from a novel multidisc dry powder inhaler.
    1. Barnes PJ. Effect of low dose formoterol and budesonide on exhaled breath in asthma. Royal Brompton and Harefield NHS Trust;
    1. Bush A. Department of Paediatrics, Imperial College School of Medicine. Royal Brompton and Harefield NHS Trust; Brompton Campus, Dovehouse Street, London, SW3 6LY, United Kingdom: Efficacy and safety of budesonide/formoterol Turbuhaler , compared to budesonide turbuhaler metered dose, in steroid using asthmatic adolescent patients, double blind, double dummy parallel group, Phase III, multicentre study.
    1. Currie GP. Are there additional anti-inflammatory effects of leukotriene receptor antagonists in persistent asthmatics receiving inhaled steroid alone and combined inhaled steroid/long acting B2-agonists? Academic Publications;

Additional references

    1. Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database of Systematic Reviews. 2008;(Issue 4) [DOI: 10.1002/14651858.CD003135.Pub4] - PubMed
    1. Adkins JC, McTavish D. Salmeterol: a review of its pharmacological properties and clinical efficacy in the management of children with asthma. Drugs. 1997;54(2):331–54. - PubMed
    1. Anonymous . Asthma Management Handbook. 6th Edition. National Asthma Campaign; Melbourne: 2006. http://www.nationalasthma.org.au/publications/amh/amhcont.htm.
    1. Bartow RA, Brogden RN. Formoterol: an update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs. 1998;55(2):302–22. - PubMed
    1. British Thoracic Society/Scottish Intercollegiate Guidelines Network [accessed 9 August 2009]; [updated June 2009];British Guidelines on Asthma Management. 2008 http://www.brit-thoracic.org.uk.

References to other published versions of this review

    1. Greenstone IR, Ni Chroinin M, Masse V, Danish A, Magdalinos H, Zhang X, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database of Systematic Reviews. 2005;(Issue 4) [DOI: 10.1002/14651858.CD005533] - PubMed

    1. * Indicates the major publication for the study

Publication types

MeSH terms

Substances